市場調查報告書
商品編碼
1368649
母乳寡糖 (HMO) 市場規模 - 按濃度(中性 HMO、酸性 HMO)、按應用(嬰兒配方奶粉、膳食補充劑、食品和飲料)及全球預測,2023 - 2032 年Human Milk Oligosaccharides (HMO) Market Size - By Concentration (Neutral HMO, Acidic HMO), By Application (Infant Formula, Dietary Supplements, Food and Beverage) & Global Forecast, 2023 - 2032 |
2023年至2032年,全球母乳寡糖市場將以22.5%的年複合成長率成長。人們對母乳寡糖(HMO)的健康益處(例如其在嬰兒免疫系統發育和腸道健康中的作用)的認知不斷提高,將推動產業成長。
此外,乳糖不耐症盛行率的上升以及嬰兒母乳餵養替代品的轉變將促進母乳低聚醣配方奶粉的銷售。根據 MedlinePlus 的估計,近 65% 的人類在嬰兒期後消化乳糖的能力會下降。此外,正在進行的母乳低聚醣在成人營養和藥品等領域的潛在應用研究將為業務成長創造新的機會。
母乳低聚醣製造商和嬰兒配方奶粉生產商之間日益加強的夥伴關係和合作將進一步促進市場成長。這種成長將得到對嬰兒營養產品中母乳低聚醣涵蓋監管支持的不斷發展的補充。這種合作和監管認可的發展將對推動該行業的成長發揮重要作用。
市場根據集中度、應用和區域進行分類。
根據集中度,到2032 年,酸性HMO 細分市場將呈現可觀的年複合成長率。人們對酸性HMO 健康益處的認知不斷提高,對專門嬰兒營養的需求不斷擴大,以及證明其在嬰兒健康方面優勢的持續研究將促進該細分市場的成長。
到2032 年,膳食補充劑應用領域將在母乳低聚醣市場中佔據顯著佔有率。消費者對HMO 潛在健康益處的認知不斷提高、其經過驗證的益生元特性,以及對功能性和營養補充劑的需求不斷擴大等因素,特別是那些針對腸道健康和免疫支持將推動該領域的成長。
從地區來看,在出生率上升、可支配收入增加以及對嬰兒營養日益重視等因素的推動下,亞太地區母乳低聚醣(HMO)市場在分析期間將以令人稱讚的年複合成長率成長。此外,人們對母乳哺育益處的認知提高以及優質嬰兒配方奶粉產品的採用將進一步推動該地區行業的成長。
The global human milk oligosaccharides market will grow at a 22.5% CAGR from 2023 to 2032. The increasing awareness of the health benefits of human milk oligosaccharides (HMOs) such as their role in infant immune system development and gut health, will fuel industry growth.
Additionally, the rising prevalence of lactose intolerance and the shift towards breastfeeding alternatives for infants will boost human milk oligosaccharides-based formula sales. According to estimates from MedlinePlus, close to 65% of the human population experiences a decline in the ability to digest lactose post-infancy. Furthermore, ongoing research into potential applications of human milk oligosaccharides in areas like adult nutrition and pharmaceuticals will create new opportunities for business growth.
The increasing partnerships and collaborations between manufacturers of human milk oligosaccharides and producers of infant formula will further augment market growth. This growth will be complemented by the ongoing evolution of regulatory support for the inclusion of human milk oligosaccharides in infant nutrition products. Such developments in cooperation and regulatory endorsement will play a significant role in driving the industry's growth.
The market is segregated based on concentration, application, and region.
Based on concentration, the acidic HMO segment will reflect a substantial CAGR through 2032. The rising awareness of the health benefits of acidic HMO, expanding demand for specialized infant nutrition, and ongoing research demonstrating their advantages in infant health will foster growth in the segment.
The dietary supplement application segment will hold a noteworthy share of the human milk oligosaccharides market by 2032. Factors such as increasing consumer awareness of the potential health benefits of HMOs, their proven prebiotic properties, and the expanding demand for functional and nutritional supplements, particularly those targeting gut health and immune support will drive growth in the segment.
Regionally, the Asia Pacific human milk oligosaccharides (HMOs) market will grow with a commendable CAGR during the analysis period, driven by factors such as increasing birth rates, rising disposable incomes, and a growing emphasis on infant nutrition. Moreover, heightened awareness of the benefits of breastfeeding and the adoption of premium infant formula products will further drive growth in the regional industry.